We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Analysis of efficacy, safety and prognostic factors of DAC-HAA treatment in Chinese pediatric patients with refractory or relapsed acute myeloid leukemia.
- Authors
Wang, Liang; Li, Chun; Xu, Fang; Cao, Fang; Zhang, Bo; Wang, Jing; Wang, Shen; Chen, Li; Li, Na; Liao, Chenglin; Liu, Hongjun
- Abstract
Hematopoietic stem cell transplantation (HSCT) is generally considered as the only effective treatment for children with relapsed/refractory (R/R) acute myeloid leukemia (AML). Achieving remission prior to HSCT affects the efficacy of the procedure and patient survival; therefore, induction therapy in children with R/R AML prior to HSCT is very important. The aim of the present study was to evaluate the clinical efficacy, prognosis and safety of 5-aza-2-deoxycytidine (DAC) combined with homoharringtonine + cytarabine + aclarubicin (HAA regimen) in the treatment of pediatric R/R AML. A total of 53 pediatric patients with R/R AML, aged 1-14 years, were treated with DAC-HAA. The overall response rate was 83.1%, with a complete remission rate of 77.4% and a partial remission rate of 5.7%. In conclusion, DAC-HAA therapy for children with R/R AML was found to be associated with a high remission rate, a short period of bone marrow suppression and a good safety profile. Therefore, DAC-HAA may be of value as a transitional regimen prior to HSCT and is worthy of clinical consideration.
- Subjects
PROGNOSIS; ACUTE myeloid leukemia; CHILD patients; HEMATOPOIETIC stem cell transplantation; SAFETY factor in engineering
- Publication
Molecular & Clinical Oncology, 2021, Vol 15, Issue 6, pN.PAG
- ISSN
2049-9450
- Publication type
Article
- DOI
10.3892/mco.2021.2431